Switch theme
Sign up to access all valuation multiples
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
2020
2
LTM Revenue $0.1M
LTM EBITDA -$1.0M
$4.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OncoZenge has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of -$1.0M.
In the most recent fiscal year, OncoZenge achieved revenue of n/a and an EBITDA of -$0.9M.
OncoZenge expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OncoZenge valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$1.0M | XXX | -$0.9M | XXX | XXX | XXX |
| EBITDA Margin | -774% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$1.0M | XXX | -$0.9M | XXX | XXX | XXX |
| EBIT Margin | -774% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$0.9M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, OncoZenge's stock price is SEK 5 (or $1).
OncoZenge has current market cap of SEK 62.8M (or $6.5M), and EV of SEK 42.6M (or $4.4M).
See OncoZenge trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.4M | $6.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, OncoZenge has market cap of $6.5M and EV of $4.4M.
OncoZenge's trades at n/a EV/Revenue multiple, and -4.9x EV/EBITDA.
Equity research analysts estimate OncoZenge's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OncoZenge's P/E ratio is not available.
See valuation multiples for OncoZenge and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.5M | XXX | $6.5M | XXX | XXX | XXX |
| EV (current) | $4.4M | XXX | $4.4M | XXX | XXX | XXX |
| EV/Revenue | 34.3x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.4x | XXX | -4.9x | XXX | XXX | XXX |
| EV/EBIT | -4.4x | XXX | -4.9x | XXX | XXX | XXX |
| EV/Gross Profit | 34.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -7.2x | XXX | XXX | XXX |
| EV/FCF | -3.8x | XXX | -4.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOncoZenge's last 12 month revenue growth is 375%
OncoZenge's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.4M for the same period.
OncoZenge's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OncoZenge's rule of X is 163% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OncoZenge and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 375% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -774% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 163% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OncoZenge acquired XXX companies to date.
Last acquisition by OncoZenge was XXXXXXXX, XXXXX XXXXX XXXXXX . OncoZenge acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OncoZenge founded? | OncoZenge was founded in 2020. |
| Where is OncoZenge headquartered? | OncoZenge is headquartered in Sweden. |
| How many employees does OncoZenge have? | As of today, OncoZenge has 2 employees. |
| Is OncoZenge publicy listed? | Yes, OncoZenge is a public company listed on STO. |
| What is the stock symbol of OncoZenge? | OncoZenge trades under ONCOZ ticker. |
| When did OncoZenge go public? | OncoZenge went public in 2021. |
| Who are competitors of OncoZenge? | Similar companies to OncoZenge include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of OncoZenge? | OncoZenge's current market cap is $6.5M |
| What is the current revenue of OncoZenge? | OncoZenge's last 12 months revenue is $0.1M. |
| What is the current revenue growth of OncoZenge? | OncoZenge revenue growth (NTM/LTM) is 375%. |
| What is the current EV/Revenue multiple of OncoZenge? | Current revenue multiple of OncoZenge is 34.3x. |
| Is OncoZenge profitable? | Yes, OncoZenge is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OncoZenge? | OncoZenge's last 12 months EBITDA is -$1.0M. |
| What is OncoZenge's EBITDA margin? | OncoZenge's last 12 months EBITDA margin is -774%. |
| What is the current EV/EBITDA multiple of OncoZenge? | Current EBITDA multiple of OncoZenge is -4.4x. |
| What is the current FCF of OncoZenge? | OncoZenge's last 12 months FCF is -$1.1M. |
| What is OncoZenge's FCF margin? | OncoZenge's last 12 months FCF margin is -892%. |
| What is the current EV/FCF multiple of OncoZenge? | Current FCF multiple of OncoZenge is -3.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
